Aardvark Therapeutics (AARD) Treasury Shares (2024)

Aardvark Therapeutics (AARD) posted Treasury Shares of $96.9 million for Q4 2024, little changed sequentially from $96.9 million in Q3 2024.

Aardvark Therapeutics (AARD) Treasury Shares (2024) Analysis & Trends

Aardvark Therapeutics has reported Treasury Shares for 1 years, with the latest figure at $96.9 million in Q4 2024.

Quarterly Treasury Shares changed N/A year-over-year to $96.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $96.9 million (changed N/A YoY) and the FY2024 annual result came in at $96.9 million, changed N/A from the prior year.
Treasury Shares was little changed at $96.9 million in Q4 2024 per AARD's latest filing, from $96.9 million in the prior quarter.
Over five years, Treasury Shares peaked at $96.9 million in Q2 2024 and troughed at $48.9 million in Q1 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Aardvark Therapeutics	147.46 Mn	73.54 Mn	-	-

Download Data